Evidence map›Paper›PMID 40523886›Full record

ArticleCell death & disease2025

Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis.

Gaoyan Tang, Xuelei Cao, Jiaqi Chen, Fu Hui, Na Xu, Yiqing Jiang, Hongmin Lu, Haifeng Xiao, Xiuming Liang, Mingzhe Ma and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gaoyan Tang *Department of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China.ORCID http://orcid.org/0000-0001-6994-1376
Xuelei Cao *Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, China.
Jiaqi Chen *Cancer Prevention and Treatment Center, The Second Hospital of Shandong University, Jinan, China.
Fu HuiDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Na XuDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Yiqing JiangDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Hongmin LuDepartment of Oncology, Shanghai Renji Hospital, Shanghai Jiaotong University medical school, Shanghai, China.
Haifeng XiaoDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Xiuming LiangDivision for Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-0202-1211
Mingzhe MaDepartment of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0001-8858-0983
Yu QianDepartment of thoracic head and neck medical oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dongli LiuDepartment of Radiation Oncology, Shanghai General Hospital, Shanghai Jiaotong University medical school, Shanghai, China.
Zhenlu WangDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Shuzhen LiuDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China. liushuzhen_wf@163.com.ORCID http://orcid.org/0000-0002-8594-4486
Guohua YuDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China. ghyry@126.com.ORCID http://orcid.org/0009-0002-8459-416X
Lei SunDepartment of Oncology, Weifang People's Hospital, the First Affiliated Hospital of Shandong Second Medical University, Weifang, China. sl786777@126.com.ORCID http://orcid.org/0000-0001-7230-7640

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is highly malignant with limited treatment options, largely due to the inherent tumoral heterogeneity and acquired resistance towards chemotherapy and immunotherapy. RG7388, a known MDM2 inhibitor, exhibited anticancer activity in TP53-wild-type (TP53

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-mdm2PyroptosisTumor Suppressor Protein p53ApoptosisCaspase 3Cell Line, TumorDrug RepositioningGasderminsHumansMutationp38 Mitogen-Activated Protein Kinasespara-AminobenzoatesPhosphate-Binding ProteinsProto-Oncogene Proteins c-bcl-2Caspase 3GasderminsGSDME protein, humanMDM2 protein, humanp38 Mitogen-Activated Protein Kinasespara-AminobenzoatesPhosphate-Binding ProteinsPMAIP1 protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mdm2Reactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID40523886
PMCPMC12170848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.